Loading
ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carcinoma.
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination and subsequent degradation of Wnt receptor complex components Frizzled and LRP6. Acts on both canonical and non-canonical Wnt signalling pathway. Acts as a tumour suppressor in the intestinal stem cell zone by inhibiting the Wnt signalling pathway, thereby restricting the size of the intestinal stem cell zone.
Open Targets scores its association with cancer at 0.55 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.94, genetic association 0.56, somatic mutation 0.47, animal model 0.41). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Adrenocortical Carcinoma.
In plain words · ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carcinoma.
ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carcinoma.
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination and subsequent degradation of Wnt receptor complex components Frizzled and LRP6.
No product in this corpus aims at ZNRF3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 1999. Earliest sequence paper UniProt cites for the protein: Dunham et al, Nature, 1999, "The DNA sequence of human chromosome 22". Source.
Sources: HGNC HGNC:18126 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9ULT6 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000183579 (association with cancer (MONDO_0004992) 0.55; (GraphQL API, CC0)); IntOGen ZNRF3 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination and subsequent degradation of Wnt receptor complex components Frizzled and LRP6. Acts on both canonical and non-canonical Wnt signalling pathway. Acts as a tumour suppressor in the intestinal stem cell zone by inhibiting the Wnt signalling pathway, thereby restricting the size of the intestinal stem cell zone. Along with RSPO2 and RNF43, constitutes a master switch that governs limb specification. Location: Cell membrane (UniProt). Locus 22q12.1 (HGNC).
Query for this target: (TITLE:"ZNRF3" OR ABSTRACT:"ZNRF3" OR TITLE:"zinc and ring finger 3" OR ABSTRACT:"zinc and ring finger 3" OR TITLE:"E3 ubiquitin-protein ligase ZNRF3" OR ABSTRACT:"E3 ubiquitin-protein ligase ZNRF3" OR TITLE:"KIAA1133" OR ABSTRACT:"KIAA1133" OR TITLE:"BK747E2.3" OR ABSTRACT:"BK747E2.3" OR TITLE:"FLJ22057" OR ABSTRACT:"FLJ22057") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZNRF3, not a curated reading list.
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
Shares Adrenocortical carcinoma, IntOGen.
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.